Simultaneous Onset of Haematological Malignancy and COVID: An
Epicovideha Survey

J 2022

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

CATTANEO, Chiara; Jon SALMANTON-GARCIA; Francesco MARCHESI; Shaimaa EL-ASHWAH; Federico ITRI et al.

Základní údaje

Originální název

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Autoři

CATTANEO, Chiara; Jon SALMANTON-GARCIA; Francesco MARCHESI; Shaimaa EL-ASHWAH; Federico ITRI; Barbora WEINBERGEROVÁ; Da Silva Maria GOMES; Michelina DARGENIO; Julio DAVILA-VALLS; Sonia MARTIN-PEREZ; Francesca FARINA; Van Doesum JAAP; Toni VALKOVIC; Caroline BESSON; Christian Bjorn POULSEN; Alberto LOPEZ-GARCIA; Pavel ZAK; Martin SCHONLEIN; Klara PIUKOVICS; Ozren JAKSIC; Alba CABIRTA; Natasha ALI; Uluhan SILI; Nicola FRACCHIOLLA; Giulia DRAGONETTI; Tatjana ADZIC-VUKICEVIC; Monia MARCHETTI; Marina MACHADO; Andreas GLENTHOJ; Olimpia FINIZIO; Fatih DEMIRKAN; Ola BLENNOW; Maria Chiara TISI; Ali S OMRANI; Milan NAVRATIL; Zdenek RACIL; Jan NOVAK; Gabriele MAGLIANO; Moraima JIMENEZ; Carolina GARCIA-VIDAL; Nurettin ERBEN; Del Principe Maria ILARIA; Caterina BUQUICCHIO; Rui BERGANTIM; Josip BATINIC; Murtadha AL-KHABORI; Luisa VERGA; Tomas SZOTKOWSKI; Michail SAMARKOS; Irati ORMAZABAL-VELEZ; Stef MEERS; Johan MAERTENS; Laszlo Imre PINCZES; Martin HOENIGL; Lubos DRGONA; Annarosa CUCCARO; Yavuz M BILGIN; Avinash AUJAYEB; Laman RAHIMLI; Stefanie GRAFE; Mariarita SCIUME; Milos MLADENOVIC; Gokce Melis COLAK; Maria Vittoria SACCHI; Anna NORDLANDER; Caroline Berg VENEMYR; Michaela HANAKOVA; Nicole GARCIA-POUTON; Ziad EMARAH; Giovanni Paolo Maria ZAMBROTTA; Raquel Nunes RODRIGUES; Raul CORDOBA; Gustavo-Adolfo MENDEZ; Monika M BIERNAT; Oliver A CORNELY a Livio PAGANO

Vydání

Cancers, Basel, MDPI, 2022, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00128418

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

haematological malignancy onset; COVID-19; treatment; outcome; prognostic factors

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 1. 2023 08:54, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Citovat

@article{2251355,
   author = {Cattaneo, Chiara and SalmantonandGarcia, Jon and Marchesi, Francesco and ElandAshwah, Shaimaa and Itri, Federico and Weinbergerová, Barbora and Gomes, Da Silva Maria and Dargenio, Michelina and DavilaandValls, Julio and MartinandPerez, Sonia and Farina, Francesca and Jaap, Van Doesum and Valkovic, Toni and Besson, Caroline and Poulsen, Christian Bjorn and LopezandGarcia, Alberto and Zak, Pavel and Schonlein, Martin and Piukovics, Klara and Jaksic, Ozren and Cabirta, Alba and Ali, Natasha and Sili, Uluhan and Fracchiolla, Nicola and Dragonetti, Giulia and AdzicandVukicevic, Tatjana and Marchetti, Monia and Machado, Marina and Glenthoj, Andreas and Finizio, Olimpia and Demirkan, Fatih and Blennow, Ola and Tisi, Maria Chiara and Omrani, Ali S and Navratil, Milan and Racil, Zdenek and Novak, Jan and Magliano, Gabriele and Jimenez, Moraima and GarciaandVidal, Carolina and Erben, Nurettin and Ilaria, Del Principe Maria and Buquicchio, Caterina and Bergantim, Rui and Batinic, Josip and AlandKhabori, Murtadha and Verga, Luisa and Szotkowski, Tomas and Samarkos, Michail and OrmazabalandVelez, Irati and Meers, Stef and Maertens, Johan and Pinczes, Laszlo Imre and Hoenigl, Martin and Drgona, Lubos and Cuccaro, Annarosa and Bilgin, Yavuz M and Aujayeb, Avinash and Rahimli, Laman and Grafe, Stefanie and Sciume, Mariarita and Mladenovic, Milos and Colak, Gokce Melis and Sacchi, Maria Vittoria and Nordlander, Anna and Venemyr, Caroline Berg and Hanakova, Michaela and GarciaandPouton, Nicole and Emarah, Ziad and Zambrotta, Giovanni Paolo Maria and Rodrigues, Raquel Nunes and Cordoba, Raul and Mendez, GustavoandAdolfo and Biernat, Monika M and Cornely, Oliver A and Pagano, Livio},
   article_location = {Basel},
   article_number = {22},
   doi = {https://doi.org/10.3390/cancers14225530},
   keywords = {haematological malignancy onset; COVID-19; treatment; outcome; prognostic factors},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey},
   url = {https://www.mdpi.com/2072-6694/14/22/5530},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2251355
AU  - Cattaneo, Chiara - Salmanton-Garcia, Jon - Marchesi, Francesco - El-Ashwah, Shaimaa - Itri, Federico - Weinbergerová, Barbora - Gomes, Da Silva Maria - Dargenio, Michelina - Davila-Valls, Julio - Martin-Perez, Sonia - Farina, Francesca - Jaap, Van Doesum - Valkovic, Toni - Besson, Caroline - Poulsen, Christian Bjorn - Lopez-Garcia, Alberto - Zak, Pavel - Schonlein, Martin - Piukovics, Klara - Jaksic, Ozren - Cabirta, Alba - Ali, Natasha - Sili, Uluhan - Fracchiolla, Nicola - Dragonetti, Giulia - Adzic-Vukicevic, Tatjana - Marchetti, Monia - Machado, Marina - Glenthoj, Andreas - Finizio, Olimpia - Demirkan, Fatih - Blennow, Ola - Tisi, Maria Chiara - Omrani, Ali S - Navratil, Milan - Racil, Zdenek - Novak, Jan - Magliano, Gabriele - Jimenez, Moraima - Garcia-Vidal, Carolina - Erben, Nurettin - Ilaria, Del Principe Maria - Buquicchio, Caterina - Bergantim, Rui - Batinic, Josip - Al-Khabori, Murtadha - Verga, Luisa - Szotkowski, Tomas - Samarkos, Michail - Ormazabal-Velez, Irati - Meers, Stef - Maertens, Johan - Pinczes, Laszlo Imre - Hoenigl, Martin - Drgona, Lubos - Cuccaro, Annarosa - Bilgin, Yavuz M - Aujayeb, Avinash - Rahimli, Laman - Grafe, Stefanie - Sciume, Mariarita - Mladenovic, Milos - Colak, Gokce Melis - Sacchi, Maria Vittoria - Nordlander, Anna - Venemyr, Caroline Berg - Hanakova, Michaela - Garcia-Pouton, Nicole - Emarah, Ziad - Zambrotta, Giovanni Paolo Maria - Rodrigues, Raquel Nunes - Cordoba, Raul - Mendez, Gustavo-Adolfo - Biernat, Monika M - Cornely, Oliver A - Pagano, Livio
PY  - 2022
TI  - Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
JF  - Cancers
VL  - 14
IS  - 22
SP  - 1-16
EP  - 1-16
PB  - MDPI
SN  - 20726694
KW  - haematological malignancy onset
KW  - COVID-19
KW  - treatment
KW  - outcome
KW  - prognostic factors
UR  - https://www.mdpi.com/2072-6694/14/22/5530
N2  - Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
ER  -

Přehled o publikaci